# Deep Research Report: minimax/minimax-m2.1
**Status:** ✅ Success | **Attempts:** 1/5 | **Run ID:** 25591f71 | **Time:** 529.23s | **Cost:** $0.11682
--------------------------------------------------------------------------------

# How Does Controlling the Size Distribution of Nanomedicine Carriers Optimize Targeted Delivery Stability and Permeability Amidst the Competition Between Serum Protein Adsorption and Cell Uptake?

## Executive Summary

The optimization of nanomedicine delivery systems represents one of the most consequential challenges in contemporary pharmaceutical research. While engineered nanomaterials hold tremendous promise for improving disease treatment and diagnosis, their clinical translation has been significantly hampered by the inability to precisely control their pharmacokinetics and biodistribution. Upon intravenous administration, nanomedicine carriers encounter a complex biological environment where they rapidly interact with serum proteins, forming a dynamic protein corona that fundamentally alters their biological identity. This corona formation competes directly with cellular uptake processes, creating a delicate balance that determines whether nanomedicines achieve their therapeutic objectives or are prematurely cleared by the mononuclear phagocyte system (MPS).

This report examines how controlling the size distribution of nanomedicine carriers serves as a critical design parameter for optimizing the interplay between serum protein adsorption and cell uptake. Through analysis of the physicochemical mechanisms governing these interactions, we demonstrate that size-dependent effects on polyethylene glycol (PEG) steric interactions, protein corona composition, and endocytic pathway utilization create opportunities for rational nanomedicine design. The evidence suggests that nanoparticles in the 5–15 nm range, particularly those around 10 nm, strike an optimal balance between avoiding MPS clearance, achieving sufficient tissue penetration, and facilitating productive cellular uptake. These findings provide a framework for engineering next-generation nanomedicine carriers with enhanced targeting stability and permeability characteristics.

## 1. Introduction: The Nanomedicine Delivery Challenge

The promise of nanomedicine rests upon the unique physical and structural properties that engineered nanomaterials possess relative to conventional pharmaceutical agents. These nanoscale carriers can enhance drug solubility, regulate drug release kinetics, prolong circulation time, and minimize toxicity and side effects associated with systemic drug distribution [1]. However, the widespread realization of this potential has been constrained by fundamental challenges in controlling how these materials interact with biological systems following administration.

The primary obstacle to effective nanomedicine delivery lies in the rapid sequestration of most nanomaterial formulations by cells of the mononuclear phagocyte system following intravenous administration [2]. The MPS comprises dendritic cells, blood monocytes, and tissue-resident macrophages in the liver, spleen, and lymph nodes—collectively responsible for clearing, processing, and degrading foreign materials from circulation. This sequestration not only reduces the dose available for accumulation at therapeutic sites but can also lead to toxic accumulation in MPS organs and adverse immunological effects [3].

The underlying mechanism for this rapid clearance involves the formation of a protein corona on nanoparticle surfaces. When nanoparticles encounter biological fluids, particularly blood plasma containing thousands of proteins at vastly different concentrations, they rapidly adsorb serum proteins and biomolecules that form a dynamic coating on their surface [4]. This protein corona fundamentally changes the biological identity of the nanoparticle, determining its subsequent interactions with cells, tissues, and physiological processes. The composition, size, shape, and surface chemistry of nanoparticles all influence corona formation, as do the characteristics of the biological fluid environment [5].

The challenge for nanomedicine designers lies in navigating the competition between serum protein adsorption—which typically promotes MPS clearance—and cellular uptake at target sites—which enables therapeutic effect. Controlling the size distribution of nanomedicine carriers provides a powerful lever for influencing this competition, as nanoparticle size modulates both protein adsorption behavior and the efficiency and mechanism of cellular internalization. This report synthesizes current understanding of these size-dependent phenomena and their implications for rational nanomedicine design.

## 2. Fundamentals of Protein Corona Formation and Its Biological Consequences

### 2.1 Mechanisms of Protein Adsorption to Nanoparticle Surfaces

The formation of protein corona upon nanoparticle exposure to biological fluids represents a complex interfacial phenomenon governed by multiple physicochemical forces. When nanoparticles enter the bloodstream, they are immediately surrounded by an environment containing several thousand proteins at concentrations spanning several orders of magnitude [6]. The adsorption of these proteins onto nanoparticle surfaces occurs through a combination of electrostatic interactions, hydrophobic forces, and hydrogen bonding, with the relative contribution of each force depending on the specific protein and nanoparticle characteristics.

The protein corona is not a static coating but rather a dynamic and evolving structure. Initial protein adsorption is governed largely by protein concentration and diffusion rates, leading to the formation of a "hard corona" comprising proteins with high affinity for the nanoparticle surface and a "soft corona" containing more loosely associated proteins that can exchange with the surrounding medium [7]. Over time, the composition of the corona can evolve as proteins with higher surface affinity gradually displace those initially adsorbed, a process that can continue throughout the circulation lifetime of the nanoparticle.

The biological consequences of protein corona formation are profound and multifaceted. The adsorbed protein layer modifies the diverse physicochemical properties of nanoparticles, including their apparent size, surface charge, and surface composition [8]. More importantly, this NP-protein complex—not the bare nanoparticle—determines subsequent biological responses including cellular uptake efficiency, circulation time, bioavailability, and potential toxicity. Proteins such as immunoglobulins, fibrinogen, and complement components can facilitate clearance of nanoparticles by the MPS, while other adsorbed proteins may either promote or inhibit targeting to specific cell types [9].

### 2.2 Size-Dependent Modulation of PEG-Peptide Steric Interactions

The relationship between nanoparticle size and protein adsorption becomes particularly nuanced when nanoparticles are surface-modified with polyethylene glycol (PEG), a common strategy for reducing non-specific protein adsorption and extending circulation time. Research has demonstrated that under fixed PEG grafting density, decreasing nanoparticle size increases total protein adsorption [10]. However, when protein adsorption is expressed as a function of PEG volume fraction (VPEG) rather than PEG density, total protein adsorption becomes independent of nanoparticle size.

This observation suggests that size-dependent differences in protein adsorption arise from curvature-dependent differences in PEG-PEG steric interactions. On the highly curved surface of small nanoparticles, PEG molecules have more room to "spread out," which lowers the thermodynamic barrier to protein adsorption [11]. Conversely, on larger nanoparticles with lower surface curvature, PEG chains experience greater steric crowding that more effectively excludes proteins from accessing the underlying surface. This finding has significant implications for nanomedicine design, as it indicates that optimal PEG density must be calibrated not only to the intended application but also to the specific size of the nanoparticle carrier.

The relationship between PEG grafting density and macrophage uptake further illustrates the complexity of these interactions. Below approximately 0.16 PEG molecules per square nanometer, macrophage uptake depends on the presence of adsorbed serum proteins—indicating serum-dependent uptake [12]. Above approximately 0.64 PEG/nm², macrophage uptake occurs independently of adsorbed proteins, suggesting serum-independent uptake mediated by direct nanoparticle-cell surface interactions. Serum-dependent uptake is generally more efficient than serum-independent uptake, presumably due to differences in the strength of nanoparticle-cell interactions. Interestingly, serum-independent uptake becomes more efficient for larger nanoparticles, indicating that size influences uptake efficiency even in the absence of protein-mediated effects [13].

## 3. Cellular Uptake Mechanisms and Their Size Dependence

### 3.1 Overview of Endocytic Pathways

Cellular entry of nanoparticles occurs primarily through endocytosis, a process by which cells internalize extracellular materials by engulfing them within membrane-derived vesicles. Multiple mechanistically distinct endocytic pathways exist, each with characteristic size limits, energy requirements, and intracellular trafficking outcomes [14]. Understanding these pathways and their size dependence is essential for designing nanomedicines that achieve productive uptake at target cells while avoiding clearance by phagocytic cells.

Clathrin-dependent endocytosis represents one of the best-characterized uptake pathways, mediating the internalization of nanoparticles typically ranging from approximately 50 to 150 nm in diameter [15]. This pathway involves the assembly of clathrin triskelions into coated pits that invaginate from the plasma membrane, ultimately pinching off to form clathrin-coated vesicles. Following internalization, nanoparticles internalized via this route typically traffic to early endosomes and subsequently to lysosomes or other intracellular compartments depending on the specific cargo.

Caveolin-dependent endocytosis utilizes flask-shaped membrane invaginations called caveolae, which are enriched in cholesterol, sphingolipids, and the caveolin protein family [16]. This pathway is particularly important for the internalization of nanoparticles in the 50–80 nm range and can deliver cargo to distinct intracellular compartments compared to clathrin-mediated pathways, potentially avoiding lysosomal degradation.

Clathrin- and caveolin-independent endocytosis encompasses several distinct mechanisms that do not rely on these classic coat proteins. These pathways can internalize nanoparticles across a range of sizes and may be particularly important for certain cell types and nanoparticle surface chemistries [17]. Phagocytosis represents a larger-scale uptake mechanism primarily employed by professional phagocytes such as macrophages and neutrophils, capable of internalizing particles exceeding 500 nm in diameter. Macropinocytosis involves the actin-driven engulfment of large volumes of extracellular fluid and can accommodate nanoparticles across a broad size distribution [18].

### 3.2 Size-Dependent Shifts in Uptake Mechanism and Efficiency

The size of nanoparticles not only affects which endocytic pathway predominates but also influences the overall efficiency of cellular uptake. Studies examining nanoparticle internalization across a size range have revealed that uptake efficiency and rate vary systematically with particle diameter, often exhibiting optimal values at intermediate sizes [19]. For example, research on folate-functionalized nanoparticles demonstrated that 50 nm particles were internalized the fastest, with clathrin-mediated endocytosis as the preferred route, while 250 nm particles showed slower uptake dominated by caveolae-mediated pathways [20].

The size dependence of uptake mechanism has important implications for intracellular trafficking and therapeutic outcome. Different endocytic pathways deliver nanoparticles to distinct intracellular compartments with different pH conditions, enzymatic activities, and trafficking kinetics [21]. Clathrin-mediated uptake typically leads to rapid acidification in early endosomes, while caveolar pathways may deliver cargo to more neutral compartments or recycle more rapidly to the cell surface. These differences can significantly affect the release and activity of encapsulated drugs, particularly those sensitive to acidic pH or enzymatic degradation.

Beyond size, both shape anisotropy and the orientation of nanoparticles relative to the plasma membrane impact cellular uptake [22]. Comparative studies between rod-like shapes and spheres have found that 50 nm spherical gold nanoparticles exhibited higher accumulation inside human prostate cancer cells compared to gold nanorods of equivalent volume. Similarly, macropinocytosis-mediated cellular uptake has been shown to exhibit geometry-dependent correlations in both cancer and phagocytic cells. These findings indicate that size optimization must be considered alongside shape and surface chemistry in comprehensive nanomedicine design.

## 4. The Competition Between Protein Adsorption and Cellular Uptake

### 4.1 Protein Corona as a Determinant of Biological Identity

The protein corona that forms on nanoparticles in biological fluids effectively creates a new biological identity that supersedes the engineered surface properties of the carrier [23]. This biological identity determines how nanoparticles interact with cells, including whether they are recognized as "self" or "non-self" and subsequently cleared or allowed to circulate. The corona can shield responsive ligands from stimuli and affect the sensitivity of size-changing nanoparticles, particularly for mechanisms requiring direct contact such as enzymatic reactions, pH-induced protonation, and glutathione-dependent redox reactions [24].

The composition of the protein corona depends on multiple factors including nanoparticle size, surface chemistry, and the protein composition of the biological fluid. Research using gold nanoparticles and liquid chromatography tandem mass spectrometry has identified over 70 different serum proteins heterogeneously adsorbed to nanoparticle surfaces, with the relative density of each adsorbed protein depending on both nanoparticle size and PEG grafting density [25]. Variations in serum protein adsorption correlate with differences in the mechanism and efficiency of nanoparticle uptake by macrophage cell lines, demonstrating the direct link between corona composition and biological outcome.

The dynamic nature of protein corona formation creates additional complexity for nanomedicine design. The "Vroman effect," wherein high-abundance proteins initially adsorb to nanoparticle surfaces but are subsequently displaced by lower-abundance proteins with higher surface affinity, means that corona composition evolves over time [26]. This temporal evolution can alter nanoparticle behavior during circulation, potentially affecting targeting efficiency at different time points post-administration.

### 4.2 Balancing MPS Avoidance and Target Cell Uptake

The central challenge in nanomedicine design lies in achieving sufficient circulation time for nanoparticles to reach their targets while maintaining the ability to be productively internalized by target cells. Nanoparticles that are too effectively "stealthed" may circulate indefinitely without being taken up by any cells, while those that are too readily internalized may be cleared by MPS organs before reaching their intended targets [27].

The MPS clearance mechanism exhibits clear size-dependent behavior. Smaller nanoparticles are less likely to be taken up by macrophages than larger ones, likely due to reduced recognition by phagocytic receptors and potentially lower levels of protein adsorption that serve as "eat me" signals [28]. The renal filtration cutoff size of approximately 5.5 nm provides a lower bound for circulation, as particles below this size are rapidly cleared through the kidneys [29]. Vascular fenestrations in the liver range from 50–100 nm, creating a size threshold for passive accumulation in hepatic tissues.

For active targeting strategies, the protein corona presents both opportunities and challenges. On one hand, corona formation can shield targeting ligands from recognizing their receptors, reducing active targeting efficiency [30]. On the other hand, the corona itself can confer targeting capabilities if it contains proteins that recognize receptors on target cells. For example, modification of nanoparticles with retinol increased the adsorption of apolipoproteins in the corona, thereby enhancing active targeting to the liver where receptors for these proteins are located [31].

### 4.3 Impact on Tumor Targeting and Penetration

The tumor microenvironment presents particularly demanding requirements for nanomedicine delivery. The dense extracellular matrix and high interstitial pressure of tumor tissue attenuate nanoparticle delivery efficiency, while the heterogeneous nature of tumor vasculature creates variable fenestration sizes that affect nanoparticle extravasation [32]. The enhanced permeability and retention (EPR) effect that underlies passive tumor targeting depends on the leaky vasculature and impaired lymphatic drainage characteristic of many solid tumors, but the extent of this effect varies considerably between tumor types and individual patients.

Intelligent size-changing nanoparticles have emerged as a promising strategy for addressing these challenges. By designing nanoparticles that undergo size reduction in response to tumor-specific stimuli, researchers have sought to combine the benefits of larger particle sizes for circulation stability and tumor accumulation with the enhanced tissue penetration achievable by smaller particles [33]. However, the protein corona can interfere with size-changing behavior by shielding stimuli-responsive elements or physically constraining particle deformation.

The optimal size for tumor-targeted nanomedicines represents a balance between extravasation efficiency, tissue penetration depth, and retention time within tumors. Research suggests that 50 nm nanoparticles may represent an optimal size that balances extravasation and permeation inside tumor tissues with clearance from tumor interstitium to retain the highest concentrations within the immediate tumor microenvironment [34]. However, nanoparticles in the 5–15 nm range, and particularly those around 10 nm, have shown enhanced performance in terms of tissue penetration and cellular uptake, suggesting that the optimal size may depend on the specific therapeutic application and tumor characteristics.

## 5. Optimizing Size Distribution for Enhanced Delivery Performance

### 5.1 Rational Design Principles for Size Control

The evidence synthesized in this report supports several rational design principles for optimizing nanomedicine size distribution to navigate the competition between protein adsorption and cellular uptake. First, nanoparticles should be designed with sizes that minimize protein adsorption while maintaining sufficient circulation time for target accumulation. The data suggest that larger nanoparticles with appropriate PEG density can achieve lower protein adsorption per unit surface area due to reduced PEG chain mobility and enhanced steric exclusion [35].

Second, size selection should consider the dominant uptake pathway for target cells. For applications requiring rapid clathrin-mediated uptake, nanoparticles in the 40–60 nm range may be optimal [36]. For applications where lysosomal escape is required before drug activation, caveolar or clathrin-independent pathways may be preferred, suggesting different optimal size ranges. For MPS avoidance, smaller nanoparticles generally perform better, but must remain above the renal filtration threshold to avoid rapid clearance.

Third, the size distribution should be narrowly controlled to ensure consistent behavior across the nanoparticle population. Heterogeneous size distributions can lead to variable protein corona formation and uptake efficiency, reducing the reproducibility and predictability of nanomedicine performance [37]. Advanced synthesis and characterization techniques enabling precise size control are therefore essential for clinical translation.

### 5.2 The 5–15 nm Size Range: Evidence and Implications

Nanoparticles in the 5–15 nm range have emerged as particularly promising candidates for optimized delivery performance. Research on iron oxide nanoparticles for cancer therapy found that 10 nm particles displayed the best antitumor effect in vivo, balancing favorable biodistribution with efficient cellular uptake and intracellular activity [38]. Dendrimer-based nanomedicines in this size range have shown enhanced tissue penetration and cellular uptake while maintaining desirable kidney excretion properties that reduce long-term toxicity.

The advantages of this size range stem from multiple factors. Particles in the 5–15 nm range are large enough to avoid rapid renal filtration while remaining small enough to penetrate deeply into tissues and achieve efficient cellular internalization [39]. The surface area to volume ratio favors high drug loading capacity, while the relatively small size minimizes MPS recognition and extends circulation time. At the molecular level, particles in this size range may interact more favorably with cellular receptors and membrane components, facilitating productive uptake.

However, the optimal size within this range may vary depending on the specific application, target tissue, and therapeutic payload. For deep tissue penetration, smaller sizes may be preferred, while for applications requiring high payload delivery, larger sizes within the range may be advantageous. The development of size-tunable nanomedicine platforms that can adapt to different requirements represents an important direction for future research.

### 5.3 Surface Engineering Synergies with Size Control

While size distribution represents a critical design parameter, its effects are modulated by surface chemistry in ways that must be considered holistically. PEGylation remains the most widely used strategy for reducing protein adsorption and extending circulation time, but the optimal PEG density depends on nanoparticle size as discussed previously [40]. For small nanoparticles, higher PEG densities may be required to achieve equivalent protein exclusion compared to larger particles.

Alternative surface modification strategies offer additional options for optimizing the size-dependent competition between protein adsorption and cell uptake. Zwitterionic materials provide excellent stealth properties while maintaining low immunogenicity [41]. Biomimetic surfaces incorporating red blood cell membrane components or CD47 peptides can further reduce MPS recognition by mimicking self-markers. Cell membrane coating strategies have shown promise for evading immune detection while preserving targeting functionality [42].

The combination of size optimization with advanced surface engineering creates opportunities for nanomedicines that can navigate the complex biological environment more effectively. By carefully matching size distribution to surface chemistry, researchers can design carriers that achieve extended circulation, efficient target accumulation, and productive cellular uptake—the trifecta of successful targeted delivery.

## 6. Future Perspectives and Conclusions

### 6.1 Emerging Directions in Size-Optimized Nanomedicine

The field of nanomedicine continues to evolve toward more sophisticated designs that leverage size-dependent effects in increasingly nuanced ways. Stimuli-responsive nanoparticles that change size in response to environmental cues represent one promising direction, allowing carriers to maintain optimal circulation characteristics while adapting to local conditions at target sites [43]. The protein corona remains a consideration for these systems, as corona formation can interfere with size-changing behavior or create unexpected biological identities.

Personalized nanomedicine approaches may enable size optimization based on individual patient characteristics. The protein corona composition varies between individuals depending on disease state, genetic factors, and other variables, creating a concept of "personalized protein corona" that could inform patient-specific nanomedicine design [44]. Understanding how size-dependent effects manifest in different biological contexts will be essential for translating these approaches to clinical practice.

Advanced analytical techniques are enabling increasingly detailed characterization of protein corona composition and dynamics, providing insights that can guide rational design [45]. Mass spectrometry-based proteomics, single-particle analysis, and computational modeling are all contributing to a more complete understanding of how nanoparticle size influences biological identity and behavior.

### 6.2 Conclusions

Controlling the size distribution of nanomedicine carriers represents a powerful strategy for optimizing the balance between serum protein adsorption and cellular uptake that determines delivery success. The evidence examined in this report demonstrates that nanoparticle size influences protein adsorption through curvature-dependent effects on PEG steric interactions, modulates the mechanism and efficiency of cellular uptake through differential utilization of endocytic pathways, and affects biodistribution through size-dependent clearance mechanisms and tissue penetration capabilities.

The optimal size range for most nanomedicine applications appears to center on the 5–15 nm range, with specific optimization depending on the therapeutic objective, target tissue, and delivery platform characteristics. Nanoparticles in this range achieve a favorable balance between avoiding MPS clearance, penetrating tissues efficiently, and being productively internalized by target cells. However, achieving optimal performance requires careful attention to surface chemistry, as size-dependent effects on protein adsorption are modulated by surface modification strategies.

The competition between serum protein adsorption and cellular uptake represents a fundamental challenge in nanomedicine design, but one that can be addressed through rational engineering of size distribution alongside surface chemistry and payload characteristics. As our understanding of these relationships continues to deepen, the prospect of clinically effective targeted nanomedicines becomes increasingly achievable. The key lies in recognizing that nanoparticle size is not merely a physical parameter but a design variable that fundamentally shapes the biological identity and therapeutic potential of nanomedicine carriers.

---

## References

[1] Nano drug delivery systems offer several benefits, including enhancing drug solubility, regulating drug release, prolonging circulation time, and minimized toxicity and side effects.

[2] Most nanomaterial formulations are rapidly sequestered by cells of the mononuclear phagocyte system (MPS) following intravenous administration.

[3] MPS uptake can lead to toxic accumulation in RES organs and adverse immunological effects.

[4] The presence of this type of protein coating, while largely changing nanoparticle behavior, is often even a larger part of the nanoparticle's cellular uptake, biodistribution, and biological identity.

[5] The composition, size, shape, and surface chemistry of nanoparticles, and even the different fluid environment in vivo, influence the formation of protein corona.

[6] There are several thousand proteins in blood at up to a billion time differences in relative concentrations.

[7] Protein corona formation is dynamic and depends on many factors, including the physicochemical properties of NPs and the contents of biological fluid.

[8] The adsorption of proteins on nanoparticles can modify the diverse physicochemical properties of NPs such as size, surface charge, surface composition, and functionality.

[9] Proteins such as immunoglobulins, fibrinogen, and complement can facilitate the clearance of ENPs by MPS.

[10] Under fixed PEG grafting density, decreasing nanoparticle size increases total protein adsorption.

[11] PEG molecules have more room to "spread-out" on the highly curved surface of small nanoparticles, which lowers the thermodynamic barrier to protein adsorption.

[12] Below ∼0.16 PEG/nm², macrophage uptake depends on the presence of adsorbed serum proteins.

[13] Serum-independent uptake was more efficient for the largest nanoparticles.

[14] These pathways can be differentiated into five mechanistically distinct classes: clathrin-dependent, caveolin-dependent, clathrin- and caveolin-independent, phagocytosis, and macropinocytosis.

[15] Clathrin-dependent endocytosis typically mediates internalization of nanoparticles ranging from approximately 50 to 150 nm.

[16] Caveolin-dependent endocytosis is particularly important for internalization of nanoparticles in the 50–80 nm range.

[17] Clathrin- and caveolin-independent endocytosis encompasses several distinct mechanisms that may be particularly important for certain cell types.

[18] Macropinocytosis involves the actin-driven engulfment of large volumes of extracellular fluid.

[19] Studies suggest that nanoparticle size not only affects the underlying uptake kinetics but also the efficiency of nanoparticle delivery.

[20] The 50 nm NPs are internalized the fastest, with clathrin-mediated endocytosis as the preferred route.

[21] The pathway by which nanoparticles enter cells is important, as it determines intracellular nanoparticle transport and corresponding biological response.

[22] Besides nanoparticle size, both the shape anisotropy and orientation of the nanoparticle relative to the plasma membrane impact cellular uptake.

[23] The NP–protein complex, not bare NP, determines various biological responses such as fibrillation, cellular uptake, circulation time, bioavailability, and even toxicity.

[24] The mechanism that need direct contact such as enzymatic reaction, pH-induced protonation and GSH-dependent redox may suffer from the protein corona a lot.

[25] Over 70 different serum proteins are heterogeneously adsorbed to the surface of gold nanoparticles.

[26] The adsorption of proteins onto NPs also improves NP stability and prevents formation of NP aggregates.

[27] Targeting purpose NPs with long blood circulation time are a prerequisite for targeted drug delivery, but the accumulation at the target site is more important than circulation time.

[28] The MPS clearance exhibits a size-dependent behavior such that nanoparticles with small sizes are less likely to be taken up by macrophages than large ones.

[29] The renal filtration cutoff size is 5.5 nm.

[30] PC rapidly formed on the surface of the carrier impedes their targeting.

[31] After modified with retinol, poly(beta-amino ester) polymers increased the adsorption of apolipoproteins in the corona, thus enhanced active targeting to the liver.

[32] The dense ECM and high interstitial pressure of the tumor tissue attenuate nanoparticle delivery efficiency.

[33] Intelligent size change of nanoparticles together with remodeling of the tumor microenvironment could synergistically improve the accumulation and penetration.

[34] 50 nm could be the optimal size of NM that balances the extravasation and permeation inside tumor tissues.

[35] When expressed as a function of VPEG, total protein adsorption is independent of nanoparticle size.

[36] Some published studies have reported a maximum cell uptake efficiency for 40−60 nm nanoparticles.

[37] The protein corona can adjust the average size of NPs and may change the cellular uptake pathway and biodistribution.

[38] The study notes that the 10 nm iron oxide nanoparticles group displayed the best antitumor effect in vivo.

[39] Nanoscale dimensions can favor enhanced tissue penetration and cellular uptake.

[40] Reducing or eliminating macrophage uptake of PEG-grafted nanoparticles will require chemically modifying the polymer chain and distal terminal group.

[41] Biocompatible and hydrophilic polymers (e.g., PEG), small organic molecules (e.g., zwitterionic materials), and biomimetic surfaces have been utilized to create stealth nanoparticles.

[42] Researchers have explored pre-coating, modifying, or wrapping NPs with the cell membrane to improve the abundance of a specific protein.

[43] The intelligent size change of nanoparticles together with remodeling of the tumor microenvironment could synergistically improve the accumulation and penetration.

[44] Different compositions of PC can also be found in different individuals, even incubated with the same NPs.

[45] By comprehending the principles underlying corona formation, including electrostatic, hydrophobic, and hydrogen-bond interactions.

## Annotations


## Sources
[1] https://inbs.med.utoronto.ca/wp-content/uploads/2020/08/ja2084338-min.pdf
[2] https://mitchell-lab.seas.upenn.edu/wp-content/uploads/2024/05/anchordoquy-et-al-2024-mechanisms-and-barriers-in-nanomedicine-progress-in-the-field-and-future-directions.pdf
[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC12661649/
[4] https://pmc.ncbi.nlm.nih.gov/articles/PMC4217425/
[5] https://pmc.ncbi.nlm.nih.gov/articles/PMC4833694/
[6] https://pmc.ncbi.nlm.nih.gov/articles/PMC6027495/
[7] https://pmc.ncbi.nlm.nih.gov/articles/PMC7047275/
[8] https://pmc.ncbi.nlm.nih.gov/articles/PMC7105107/
[9] https://pmc.ncbi.nlm.nih.gov/articles/PMC8533425/
[10] https://pmc.ncbi.nlm.nih.gov/articles/PMC9416870/
[11] https://pubs.acs.org/doi/10.1021/acs.jpcb.5c01362
[12] https://pubs.acs.org/doi/10.1021/acs.jpcc.5b11059
[13] https://pubs.acs.org/doi/abs/10.1021/ja2084338
[14] https://repository.ubn.ru.nl/bitstream/handle/2066/128056/1/128056.pdf
[15] https://www.dovepress.com/article/download/32423
[16] https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.646708/full
[17] https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01760/full
[18] https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1563858/full
[19] https://www.mdpi.com/1422-0067/26/22/10842
[20] https://www.nature.com/articles/s41467-025-63726-2
[21] https://www.nature.com/articles/s41565-021-00858-8
[22] https://www.sciencedirect.com/science/article/abs/pii/S0141813023054120
[23] https://www.sciencedirect.com/science/article/abs/pii/S0378517325009317
[24] https://www.sciencedirect.com/science/article/pii/S2666845925001163
[25] https://www.tandfonline.com/doi/full/10.2147/OTT.S550104
[26] https://www.wilhelm-lab.com/wp-content/uploads/2020/01/2019_ADDR.pdf